Newsletter
Ivermectin for Mild to Moderate COVID-19, Persistent Symptoms Following COVID-19, Review of Hypercalcemia, and more

JAMA Editor’s Summary

Ivermectin for Mild to Moderate COVID-19, Persistent Symptoms Following COVID-19, Review of Hypercalcemia, and more

Editors' Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the , issue.
October 25, 2022

Ivermectin for Mild to Moderate COVID-19, Persistent Symptoms Following COVID-19, Review of Hypercalcemia, and more

Editors’ Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the October 25, 2022, issue.

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Adopting Clinical Trial Technology: The Key to Success for Patients, Sites, & Researchers Adoption of new clinical trial technologies is critical to success. These innovations can lift patient burden, improve patient engagement, and increase equity and access to clinical trials.